AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35112343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with truncating variants
Number of subjects: 607
Study 35112343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with genes not belonging to the BBSome or chaperonin-like genes
Number of subjects: 607
Study 35112343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome individuals with diverse uropathies
Number of subjects: 607
Study 35112382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib (150 mg single dose)
Number of subjects: 0
Study 35112882 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization cardiovascular events (myocardial infarction, stroke, hospitalization for unstable angina or heart failure)
Number of subjects: 18144
Study 35112882 — intervention group
Group type: COMPARATOR
Intervention: No postrandomization cardiovascular events
Number of subjects: 18144
Study 35112882 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization myocardial infarction
Number of subjects: 18144
Study 35112882 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization heart failure
Number of subjects: 18144
Study 35112886 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG LVH defined by Cornell criteria
Number of subjects: 596
Study 35112886 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG LVH defined by Sokolow-Lyon criteria
Number of subjects: 596
Study 35112886 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG LVH defined by Romhilt-Estes criteria
Number of subjects: 596
Study 35112886 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ECG LVH
Number of subjects: 596
Study 35112928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pcrit measurement during drug-induced sleep endoscopy (DISE)
Number of subjects: 13
Study 35112976 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR concentrations
Number of subjects: 968
Study 35112976 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR as a predictor
Number of subjects: 968
Study 35112976 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic utility of suPAR
Number of subjects: 968
Study 35113020 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 29
Study 35113020 — intervention group
Group type: COMPARATOR
Intervention: Smartphone App
Number of subjects: 29
Study 35113028 — intervention group
Group type: EXPERIMENTAL
Intervention: VR food cues
Number of subjects: 175
Study 35113028 — intervention group
Group type: COMPARATOR
Intervention: RL food cues
Number of subjects: 175
Study 35113285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym013 at 4 mg/kg once-weekly (changed to biweekly due to adverse events)
Number of subjects: 32
Study 35113285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym013 at 15 mg/kg biweekly (Q2W)
Number of subjects: 32
Study 35113285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym013 (various doses)
Number of subjects: 32
Study 35113363 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) treatment for rheumatoid arthritis
Number of subjects: 824
Study 35113812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresolimumab (TGF-β neutralizing antibody)
Number of subjects: 8
Study 35113830 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour device
Number of subjects: 34
Study 35113860 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Health and Depression (BA-HD)
Number of subjects: 8
Study 35113934 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-γ (IFN-γ) administration
Number of subjects: 0
Study 35114059 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical thrombectomy
Number of subjects: 250
Study 35114169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for 2 years or until disease progression
Number of subjects: 112
Study 35114169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 112
Study 35114404 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs suspected of inducing APS (14 drugs identified)
Number of subjects: 790
Study 35114404 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian disproportionality indicator (information component, IC)
Number of subjects: 790
Study 35114739 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Functioning
Number of subjects: 0
Study 35114807 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 64
Study 35114814 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy after Synergy bioresorbable-polymer everolimus-eluting stent implantation
Number of subjects: 0
Study 35115084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 35115084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 35115085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val)
Number of subjects: 367
Study 35115167 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES)
Number of subjects: 36
Study 35115195 — intervention group
Group type: EXPERIMENTAL
Intervention: AKS-452 22.5 µg
Number of subjects: 60
Study 35115195 — intervention group
Group type: EXPERIMENTAL
Intervention: AKS-452 45 µg
Number of subjects: 60
Study 35115195 — intervention group
Group type: EXPERIMENTAL
Intervention: AKS-452 90 µg
Number of subjects: 60
Study 35115195 — intervention group
Group type: EXPERIMENTAL
Intervention: AKS-452 (all doses)
Number of subjects: 60
Study 35115306 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (radiotherapy with or without chemotherapy)
Number of subjects: 32
Study 35115349 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment success factors
Number of subjects: 10
Study 35115349 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment rates
Number of subjects: 10
Study 35115444 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic sterilization
Number of subjects: 29971
Study 35115610 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Breathhold (RBH)
Number of subjects: 20
Study 35115610 — intervention group
Group type: COMPARATOR
Intervention: Free Breathing (FTBH)
Number of subjects: 20
Study 35115707 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 vaccination with modified hemagglutinin (HA) containing Phe45 residue
Number of subjects: 0
Study 35115707 — intervention group
Group type: COMPARATOR
Intervention: Standard H2 vaccination without modification
Number of subjects: 0
Study 35116390 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision plus one port laparoscopic surgery (SILS plus one) with ERAS management
Number of subjects: 120
Study 35118382 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliadel 7.7 mg implant (up to 8 wafers, 61.6 mg of carmustine)
Number of subjects: 506
Study 35118382 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliadel 7.7 mg implant
Number of subjects: 506
Study 35118814 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID cohort
Number of subjects: 81
Study 35118814 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID cohort
Number of subjects: 81
Study 35118821 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg once daily from day 8 to day 71
Number of subjects: 0
Study 35118821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching enzalutamide) on day 1
Number of subjects: 0
Study 35118823 — intervention group
Group type: EXPERIMENTAL
Intervention: mCMP-registry (investigator-initiated prospective registry)
Number of subjects: 0
Study 35118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven approach
Number of subjects: 0
Study 35118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis-driven approach
Number of subjects: 0
Study 35118915 — intervention group
Group type: EXPERIMENTAL
Intervention: Metatranscriptomic sequencing of bronchial biopsies
Number of subjects: 0
Study 35119037 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 mg once every 28 days for up to 24 weeks after conservative surgery for DIE
Number of subjects: 384
Study 35119351 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-PDI/T (Craniofacial Pain and Disability Inventory - Turkish version)
Number of subjects: 0
Study 35119374 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention (2-year duration, personalized health coaching program targeting modifiable risk factors for AD)
Number of subjects: 0
Study 35119374 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 0
Study 35119374 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention
Number of subjects: 0
Study 35119377 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference groups
Number of subjects: 200
Study 35119377 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person groups
Number of subjects: 200
Study 35119377 — intervention group
Group type: COMPARATOR
Intervention: Web-based videos
Number of subjects: 200
Study 35119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (NAC) for early TN ILC
Number of subjects: 86
Study 35119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (NAC) for early HER2+ ILC
Number of subjects: 86
Study 35119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Early TN ILC
Number of subjects: 86
Study 35119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Early HER2+ ILC
Number of subjects: 86
Study 35119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced TN ILC
Number of subjects: 86
Study 35119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced HER2+ ILC
Number of subjects: 86
Study 35120043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters of double triggering and ineffective inspiratory efforts
Number of subjects: 180
Study 35120446 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line anti-TNF therapy for UC
Number of subjects: 287
Study 35120446 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line anti-TNF therapy for CD
Number of subjects: 287
Study 35120446 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line anti-TNF therapy for both UC and CD
Number of subjects: 287
Study 35120657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study 35120668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program targeting weight management during menopause
Number of subjects: 27
Study 35120668 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 27
Study 35120668 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with other women affected by menopause
Number of subjects: 27
Study 35120836 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35120987 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of primary ciliary dyskinesia pulmonary exacerbations
Number of subjects: 0
Study 35120987 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing inflammation
Number of subjects: 0
Study 35121604 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a multifaceted CRRT quality assurance and improvement programme
Number of subjects: 0
Study 35121604 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation group
Number of subjects: 0
Study 35121604 — intervention group
Group type: COMPARATOR
Intervention: Post-implementation group
Number of subjects: 0
Study 35121676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via telehealth, four-session protocol, details on dosage and duration not specified.
Number of subjects: 0
Study 35121719 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity single vision contact lens (SVCL)
Number of subjects: 25
Study 35121719 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal D +2.50 add
Number of subjects: 25
Study 35121719 — intervention group
Group type: EXPERIMENTAL
Intervention: NaturalVue Multifocal
Number of subjects: 25
Study 35121763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) using Omron HBF-306C
Number of subjects: 0
Study 35121763 — intervention group
Group type: COMPARATOR
Intervention: Dual X-ray absorptiometry (DXA)
Number of subjects: 0
Study 35121899 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 or AZD1222 vaccines (two doses, administered 12 weeks apart)
Number of subjects: 585
Study 35121899 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 or AZD1222 vaccines
Number of subjects: 585
Study 35121899 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous SARS-CoV-2 infection
Number of subjects: 585
Study 35121899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD20 treatment
Number of subjects: 585
Study 35121950 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Number of subjects: 94
Study 35121950 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA clearance during treatment
Number of subjects: 94
Study 35122060 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiation, ipilimumab, and nivolumab
Number of subjects: 65
Study 35122060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation (per-protocol analysis)
Number of subjects: 65
Study 35122234 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning module for neuromuscular monitoring
Number of subjects: 6525
Study 35122371 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) with intravenous thrombolysis (IVT)
Number of subjects: 272
Study 35122371 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT) alone
Number of subjects: 272
Study 35122371 — intervention group
Group type: COMPARATOR
Intervention: IVT (in a second PS-matched analysis)
Number of subjects: 272
Study 35122700 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2780301 plus weekly paclitaxel
Number of subjects: 51
Study 35122887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanibit electronic HH system
Number of subjects: 27
Study 35123074 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based care (V1 to V2)
Number of subjects: 21
Study 35123074 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-informed care (V2 to V3)
Number of subjects: 21
Study 35123422 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD)
Number of subjects: 20
Study 35123422 — intervention group
Group type: COMPARATOR
Intervention: Biochemical assessments (serum free light chain and M-component)
Number of subjects: 20
Study 35123437 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 12000
Study 35123437 — intervention group
Group type: COMPARATOR
Intervention: Control group of non-vaccinated patients
Number of subjects: 12000
Study 35123460 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional corrective exercise therapy (TDCET)
Number of subjects: 144
Study 35123460 — intervention group
Group type: COMPARATOR
Intervention: Generalized exercise therapy (Control Group)
Number of subjects: 144
Study 35123544 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 21
Study 35123562 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-venous ECMO for COVID-19
Number of subjects: 308
Study 35123562 — intervention group
Group type: COMPARATOR
Intervention: Veno-venous ECMO for H1N1
Number of subjects: 308
Study 35123640 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids-Ruxolitinib
Number of subjects: 23
Study 35123640 — intervention group
Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 23
Study 35123640 — intervention group
Group type: COMPARATOR
Intervention: Free-aGVHD
Number of subjects: 23
Study 35123771 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax (ABT-737 analogue) monotherapy at 150 mg daily for 7-14 days, then increased to 250 mg daily
Number of subjects: 46
Study 35123771 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax (ABT-737 analogue) monotherapy
Number of subjects: 46
Study 35123853 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory food index (IFI) score, adjusted for multiple covariates
Number of subjects: 9909
Study 35123853 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory food index (IFI) score, adjusted for sociodemographic factors
Number of subjects: 9909
Study 35123868 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-onset type 2 diabetes (T2D)
Number of subjects: 677
Study 35124074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemospray (hemostatic powder)
Number of subjects: 67
Study 35124236 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-LM core ontology
Number of subjects: 0
Study 35124236 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-LM data model
Number of subjects: 0
Study 35124236 — intervention group
Group type: EXPERIMENTAL
Intervention: Top/core/domain/local ontological levels
Number of subjects: 0
Study 35124411 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum doublet chemoradiation (Cohort 1)
Number of subjects: 40
Study 35124411 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum doublet cytotoxic chemotherapy ± immunotherapy (Cohort 2)
Number of subjects: 40
Study 35124411 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiation (Cohort 3)
Number of subjects: 40
Study 35124411 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment samples (all cohorts)
Number of subjects: 40
Study 35124680 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous PCO2 measurement
Number of subjects: 110
Study 35124680 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous PO2 measurement
Number of subjects: 110
Study 35124680 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous blood gas measurement system
Number of subjects: 110
Study 35124888 — intervention group
Group type: EXPERIMENTAL
Intervention: FAME-iSS intervention (Fatigue and Activity Management Education in Systemic Sclerosis) for 6 weeks
Number of subjects: 4
Study 35124888 — intervention group
Group type: EXPERIMENTAL
Intervention: FAME-iSS intervention
Number of subjects: 4
Study 35125401 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (2L targeted therapy)
Number of subjects: 27
Study 35125401 — intervention group
Group type: COMPARATOR
Intervention: Axitinib (2L targeted therapy)
Number of subjects: 27
Study 35125401 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (1L targeted therapy)
Number of subjects: 27
Study 35125476 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol interactive toxicity beliefs
Number of subjects: 408
Study 35126362 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 at a dose of 25 μg
Number of subjects: 30
Study 35126362 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 at a dose of 100 μg
Number of subjects: 30
Study 35126362 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOV2S measurements
Number of subjects: 30
Study 35126471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Number of subjects: 0
Study 35126524 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rituximab
Number of subjects: 0
Study 35126524 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) rituximab
Number of subjects: 0
Study 35127744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound evaluation (LUS)
Number of subjects: 0
Study 35127778 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA algae oil supplement (3.15 g daily for 6 months)
Number of subjects: 68
Study 35127778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 35128142 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (HF-rTMS)
Number of subjects: 90
Study 35128142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 90
Study 35128142 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 90
Study 35128142 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS and iTBS
Number of subjects: 90
Study 35128365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sayana Press injected every 4 months (3 treatment cycles) for 12 months
Number of subjects: 750
Study 35128365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sayana Press injected in the abdomen
Number of subjects: 750
Study 35128365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sayana Press injected in the thigh
Number of subjects: 750
Study 35128365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sayana Press injected in the arm
Number of subjects: 750
Study 35128367 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP acceptability
Number of subjects: 542
Study 35128367 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation/uptake
Number of subjects: 542
Study 35128512 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5
Number of subjects: 540
Study 35128512 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1
Number of subjects: 540
Study 35128512 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd26
Number of subjects: 540
Study 35128512 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Number of subjects: 540
Study 35128512 — intervention group
Group type: EXPERIMENTAL
Intervention: BBIBP-CorV
Number of subjects: 540
Study 35128512 — intervention group
Group type: COMPARATOR
Intervention: Serum neutralizing capacity
Number of subjects: 540
Study 35128512 — intervention group
Group type: COMPARATOR
Intervention: Safety outcome
Number of subjects: 540
Study 35128529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose split-virus influenza vaccine (HD-SVV)
Number of subjects: 582
Study 35128529 — intervention group
Group type: COMPARATOR
Intervention: Standard dose split-virus influenza vaccine (SD-SVV)
Number of subjects: 582
Study 35128529 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HD-SVV, SD-SVV)
Number of subjects: 582
Study 35128529 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior season influenza vaccination
Number of subjects: 582
Study 35128939 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide; specific dosage and duration not mentioned
Number of subjects: 0